Featured Research

from universities, journals, and other organizations

Experimental Anti-cancer Synthetic Molecule Targets Tumor Cell Growth And Angiogenesis

Date:
June 20, 2008
Source:
Public Library of Science
Summary:
A recent study describes a new candidate anti-cancer drug, HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by independently targeting tumor cell growth and tumor. The molecular target of HB-19 is nucleolin expressed on the surface of all activated cells, in particular rapidly growing tumor cells and endothelial cells that play a key role in angiogenesis.

A recent study conducted by three French CNRS (Centre National de la Recherche Scientifique) laboratories describes a new candidate anti-cancer drug, named HB-19. In contrast to conventional anti-cancer drugs, HB-19 has a dual mechanism of action by its capacity to target independently both tumor cell growth, as well as tumor angiogenesis (formation of new blood vessels which bring necessary nutrients and oxygen to the tumor mass).

The molecular target of HB-19 is nucleolin expressed on the surface of all activated cells, in particular rapidly growing tumor cells and endothelial cells that play a key role in angiogenesis. This work was directed by Ara Hovanessian.

Nucleolin is one of the major proteins of the nucleus, but it is also expressed on the cell surface where it serves as a binding protein for variety of ligands implicated in cell proliferation, differentiation, adhesion, mitogenesis and angiogenesis. The specific binding of HB-19 to surface-expressed nucleolin leads to internalization of the complex followed by degradation of this multifunctional protein.

Using various in vitro and in vivo experimental models, the authors show that HB-19 is a potent inhibitor of tumor cell growth and angiogenesis. In mice grafted with human breast tumor cells, HB-19 treatment markedly suppresses the progression of tumor development, and in some cases eliminates measurable tumors while displaying no toxicity to normal tissue.

The in vivo antitumoral action of HB-19 in this mouse model (i.e. inhibition of tumor development) is comparable to that of 5-fluorouracil, a drug that is used to treat several types of human cancer. However, 5-fluorouracil has toxic effects on circulating white blood cells whereas HB-19 treatment demonstrated no observable toxicity in this study. Another possible advantage of HB-19 over existing anti-cancer drugs is its reproducible synthesis by conventional techniques to generate a stable product that is readily soluble in physiological solutions.

The direct action of HB-19 on tumor growth and angiogenesis fulfills the criteria for an efficient anticancer drug, since combination therapy targeting both of these events is considered an optimal strategy in cancer management. In view of such dual inhibitory action, reproducible synthesis, high stability, selective tissue retention, and in vivo lack of toxicity, HB-19 may be a promising candidate for evaluation in future clinical trials.


Story Source:

The above story is based on materials provided by Public Library of Science. Note: Materials may be edited for content and length.


Journal Reference:

  1. Destouches et al. Suppression of Tumor Growth and Angiogenesis by a Specific Antagonist of the Cell-Surface Expressed Nucleolin. PLoS One, 2008; 3 (6): e2518 DOI: 10.1371/journal.pone.0002518

Cite This Page:

Public Library of Science. "Experimental Anti-cancer Synthetic Molecule Targets Tumor Cell Growth And Angiogenesis." ScienceDaily. ScienceDaily, 20 June 2008. <www.sciencedaily.com/releases/2008/06/080617204455.htm>.
Public Library of Science. (2008, June 20). Experimental Anti-cancer Synthetic Molecule Targets Tumor Cell Growth And Angiogenesis. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2008/06/080617204455.htm
Public Library of Science. "Experimental Anti-cancer Synthetic Molecule Targets Tumor Cell Growth And Angiogenesis." ScienceDaily. www.sciencedaily.com/releases/2008/06/080617204455.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins